Myosin-binding protein C (MyBP-C) binds to myosin with two binding sites, one close to the N terminus and the other at the C terminus. Here we present the solution structure of one part of the N-terminal binding site, the third immunoglobulin domain of the cardiac isoform of human MyBP-C (cC2) together with a model of its interaction with myosin. Domain cC2 has the ␤-sandwich structure expected from a member of the immunoglobulin fold. The C-terminal part of the structure of cC2 is very closely related to telokin, the myosin binding fragment of myosin light chain kinase. Domain cC2 also contains two cysteines on neighboring strands F and G, which would be able to form a disulfide bridge in a similar position as in telokin. Using NMR spectroscopy and isothermal titration calorimetry we demonstrate that cC2 alone binds to a fragment of myosin, S2⌬, with low affinity (k D ‫؍‬ 1.1 mM) but exhibits a highly specific binding site. This consists of the C-terminal surface of the CCFGA ␤-sheet, which includes Glu 301 , a residue mutated to Gln in the disease familial hypertrophic cardiomyopathy. The binding site on S2 was identified by a combination of NMR binding experiments of cC2 with S2⌬ containing the cardiomyopathy-linked mutation R870H and molecular modeling. This mutation lowers the binding affinity and changes the arrangement of side chains at the interface. Our model of the cC2-S2⌬ complex gives a first glimpse of details of the MyBP-C-myosin interaction. Using this model we suggest that most key interactions are between polar amino acids, explaining why the mutations E301Q in cC2 and R870H in S2⌬ could be involved in cardiomyopathy. We expect that this model will stimulate future research to further refine the details of this interaction and their importance for cardiomyopathy.
importance of large multidomain proteins such as Nebulin, Titin, and MyBP-C 2 for the correct assembly of muscle proteins is well established (1, 2) , and for at least one of them, MyBP-C, there is also evidence for its contribution to the regulation of muscle contraction via an influence on myosin head group arrangement (3) (4) (5) (6) (7) . MyBP-C is a large (ϳ140 kDa) multidomain protein (8, 9) that is located in the thick filament (10) , where it is attached to myosin via two binding sites: one in its C terminus for the LMM subfragment (11, 12) and the other one at its N terminus for the S2 subfragment (13) (Fig. 1, A and B) . MyBP-C binding to titin is expected to account for its regular appearance in muscle in 11 transverse stripes in intervals of 43 nm throughout the A-band. MyBP-C is made of 11 domains, 8 immunoglobulin, and 3 fibronectin type III and several linkers (14) (Fig. 1A ). It exists in three different isoforms: fast and slow skeletal as well as cardiac. The cardiac isoform is highly distinct from the skeletal isoforms by several substantial insertions in some linkers, right in the middle of the immunoglobulin domain cC5 (15) , and an entire domain at the N terminus (cC0).
The N-terminal myosin binding site contains two immunoglobulin domains connected by a long linker sequence of ϳ100 amino acids known as the mybpc motif (3) . The mybpc part of the binding site in cardiac MyBP-C contains several phosphorylation sites (3) . Phosphorylation of this motif is possible by cAMP-dependent protein kinase (cAPK) (7) or a calcium/calmodulin-regulated kinase (16) and modulates the interaction of the N-terminal MyBP-C binding site with myosin S2 (7) . Phosphorylation of MyBP-C results in a rearrangement of the myosin S1 cross-bridges and the structure of the thick filament (4, 17) . These structural rearrangements have an impact on muscle performance (6) . The importance of this interaction is further emphasized by the identification of mutations linked to familial hypertrophic cardiomyopathy (FHC) 3 in the S2 subfragment that leave the structure of the coiled-coil intact but interfere with binding to MyBP-C (13) . These mutations are located in the first 125 residues of S2 (see Fig. 1B ). This part of S2, dubbed S2⌬, was shown to be sufficient for binding to MyBP-C (13) .
As part of a long term investigation to understand the structure-function relationships of MyBP-C and how they are related to FHC we have initiated the structural analysis of the N-terminal myosin S2 binding site in human cardiac MyBP-C. We have determined the NMR structure of one of the two IgI domains, cC2, that together with the mybpc motif constitute the binding site for the S2 subfragment. We have also mapped the binding site for the myosin S2 on cC2 by NMR spectroscopy and produced a model for the complex cC2-S2⌬ based on binding experiments using the FHC-related mutation R870H in S2 and the charge complementarity between the proteins.
MATERIALS AND METHODS
Sample Preparation-Domain cC2 (residues 645-771 of human cardiac MyBP-C) was cloned in vector pET8c and expressed and purified as described previously for domain cC5 (15) . Isotope-enriched samples of cC2 were obtained by growing the bacteria in M9 minimal medium supplemented with 15 N-ammonium chloride (Cambridge Isotope Laboratories, Andover, MA) and/or uniformly 13 C-enriched glucose as the unique sources of nitrogen and carbon, respectively. Wild-type and mutant S2⌬ (residues 838 -961 from human cardiac muscle ␤ myosin) were cloned in vector pET8c and expressed as described previously (13) .
Sequence Analysis-For the alignment of cC2 in Fig. 2 sequences were extracted from the SwissProt data base as provided by the EBI. Data base entries used were MYPC_HUMAN (residues 645-771) for human cardiac MyBP-C, MYPC_ MOUSE (residues 641-767) for mouse cardiac MyBP-C, MYPC_CHICK (residues 644 -769) for chicken cardiac MyBP-C, MYPF_HUMAN (residues 544 -651) for human fast skeletal MyBP-C, MYPS_HUMAN (residues 525-631) for human slow skeletal MyBP-C, MYPF_CHICK (residues 530 -629) for chicken fast skeletal MyBP-C, and MYPS_RAT (residues 144 -241) for rat slow skeletal MyBP-C; the complete FIGURE 1. A, domain layout and protein-protein interaction sites of cardiac MyBP-C. IgI domains are shown in light gray (labeled C0 -C5, C8, and C10), Fn3 domains are in black (labeled C6, C7, and C9), and sequences of unknown structure are shown as gray-shaded regions connecting domains. The sequence connecting domains C0 and C1 is known as proline/alanine-rich (pa), the region connecting domains C1 and C2 contains the mybpc motif. Interaction sites as reported in the literature are indicated by vertical arrows, which start at the region of MyBP-C responsible for the interaction and point to the interacting protein. The size of the binding sites on MyBP-C is indicated by horizontal bars at the base of the arrows. B, overview of the myosin molecule with important functional and structural regions labeled. S1 is the S1 actin binding subfragment, ELC is the essential light chain, RLC is the regulatory light chain, S2 is the S2 fragment, HMM is the heavy meromyosin fragment, LMM is the light meromyosin fragment, and S2⌬ is the short fragment of S2 used in this work close to the junction of the S2 fragment with the light chain region and S1 fragment. FIGURE 2. Alignment of sequences of domain C2 from various MyBP-C isoforms and species as well as sequences of extensively characterized IgI domains with known structures. Special features of cardiac domain C2 are indicated above the alignment: red boxes mark amino acids that show significant chemical shift perturbations of the backbone amide group in the titration with wild-type S2⌬, residues with side chains in contact with S2⌬ in our model of complex-A are indicated by blue boxes, the normally conserved proline of the IgI fold that is a histidine in cC2 is marked with a green box, the one surface amino acid of C2 not involved in S2⌬ binding that accommodates opposite charges is indicated by a cyan bar, and the two cysteines that are capable of forming a disulfide bond are indicated by black arrows. The secondary structure of cardiac domain C2 is shown below the alignment. Amino acids in the alignment are colored according to their property if that is conserved in a position in a sufficient number of sequences as described under "Materials and Methods." MyBP-C amino acid sequences corresponding to PDB entries for domains M5 (1nct and 1ncu) and I27 (1tit) were from human cardiac titin, and the complete amino acid sequence of PDB entry 1tlk was from human telokin. The numbering of cC2 in this work is based on the cC1C2 construct (13) studied in parallel to facilitate comparison of experimental data. In this numbering scheme residue number 1 is the first residue of domain cC1 in the cC1C2 construct, which is residue 151 in the data base entry MYPC_HUMAN. Consequently, the first residue of domain cC2 has the number 291. Initial sequence alignments were produced using ClustalW (18) . Parameters used were: gap extension penalty: 10.0; gap opening penalty: 20.0; weight matrix: blosum; hydrophilic gaps: on; ktuple: 1; window: 5. The resulting alignment was then corrected by accounting for the known structures by shifting insertions from secondary structure elements and into the loops connecting them. The alignment is displayed in ClustalX version 1.81 (19) . Coloring of residues is based on residue and property specific thresholds (red: negatively charged, threshold ϭ 60%; blue: positively charged, threshold ϭ 60%; pink: hydrophilic, threshold ϭ 60%; green hydrophobic, threshold ϭ 60%; and orange: glycine, threshold ϭ 50%).
ITC-The titration was carried out on a VP-ITC instrument (MicroCal, Inc., Northampton, MA). S2⌬ solution (ϳ993 M) was titrated into cC2 solution (ϳ90 M, graph A in Fig. 6 ). The experiment and its analysis were designed according to a previous study (20) . To compensate for the expected low affinity, high protein concentrations were used, and the stoichiometry was set to 1:1 in the analysis. The titration consisted of a preliminary 3-l injection (neglected in data analysis) followed by 19 subsequent 15-l injections. 4 min were left between each injection. The reference cell was filled with distilled water. To account for heats of dilution and mechanical mixing, a control titration was performed by injection of the ligand into buffer (graph B in Fig. 6 ); binding data were corrected by subtraction of the dilution data prior to curve fitting. Corrected binding data were processed using the Origin ITC analysis software package supplied by MicroCal.
NMR Spectroscopy-NMR data were collected with 0.8 mM protein samples containing 20 mM phosphate buffer at pH 7.0, 50 mM NaCl, 2 mM dithiothreitol, 1 mM EDTA, and 0.02% NaN 3 . Each sample was prepared in 350 l of 95% (v/v) H 2 O/5% D 2 O, using Shigemi microcells. NMR spectra were acquired at 25°C on either a 600-MHz Bruker AVANCE DRX spectrometer or an 800-MHz Varian Inova spectrometer. Spectra were processed with NMRpipe (21) and analyzed using ANSIG (22 measured with a proton saturation period of 3 s. Relaxation rates were extracted from the time series by exponential fits using customized macros in Mathematica. Relaxation rates were initially used to obtain the rotational correlation time from R 1 /R 2 ratios using a subset of residues chosen to be least affected by large amplitude fast and slow time scale motions (24) . Using the thus obtained value of c a Lipari-Szabo analysis (25, 26) was performed for all individual residues.
To calculate the total average change in backbone amide 1 H N and 15 N chemical shifts for each resonance, the following equation was applied,
where ⌬␦( 15 N) and ⌬␦( 1 H N ) are the chemical shift changes in hertz. The change in total chemical shift was then calculated for each identified residue, with the exception of those whose resonances had broadened past detectability in the 15 N HSQC NMR spectra. The standard deviation associated with each dataset was also calculated.
Structure Calculation-Structure calculation is based on simulated annealing molecular dynamics (27) according to the ARIA protocol (version 1.1) for the incorporation of ambiguous distance restraints (28) . All standard parameters were used with the exception of the number of structures to be calculated in iteration 8, which was increased from 20 to 200, with the number of structures to be kept to 100, and the number of structures for the water refinement was set to 30. A total of 214 unambiguous proton-proton distances from NOESY spectra were used as a starting set of distance constraints together with 32 hydrogen bond constraints for protons in residues having the appropriate ␤-sheet-specific interstrand NOEs and 108 and dihedral angle constraints from a chemical shift analysis by TALOS (29) . Dihedral restraints were only added for those residues that had a substantial number of NOE distances and were thus assumed to be in a well defined conformation. 3071 unassigned NOEs from three-dimensional 15 N and 13 C NOESY-HSQC experiments were introduced as ambiguous distance constraints. After 8 cycles of ARIA, 2014 of these were unambiguously assigned. After the final iteration, only structures were selected that had no violation of NOE constraints above 0.5 Å. A total of 28 structures fulfilled this criterion. The structure was deposited in the protein data bank, under accession code 1PD6.
Molecular Modeling-For all modeling the NMR structure of MyBP-C domain C2 as reported in this report together with the recently reported x-ray structure of the S2⌬ fragment of myosin (PDB entry 2FXM) (30) were used. To model the complex cC2-S2⌬, we have initially investigated the surface charge complementarity between cC2 and S2⌬. We have calculated the electrostatic potential of each protein separately using Divcon with a PM3 Hamiltonian, coupled with a dielectric continuum model (Poisson-Boltzmann) for the solvent effect (31, 32) using a dielectric constant of 80 for water and 1 for the protein. The electrostatic potential calculation was accomplished for S2⌬ using its recent x-ray structure, PDB code 2FXM, which comprises amino acids 838 -963 of human cardiac ␤-myosin for monomer A and residues 850 -961 for monomer B. Residues Pro 838 to Met 849 were added to monomer A based on the conformation of these residues in monomer B and minimized using Amber6 (33) . The electrostatic potential of the proteins was mapped on their individual molecular surfaces and visualized using GRASP (34) . The surface potential of both proteins was then visually inspected to identify charge complementary regions. As a result of this analysis we assumed that the potential binding site of cC2 to S2⌬ will be in the region of residues Pro 838 to Asn
885
, because of the good charge complementarity with cC2. This region was split into three fragments (A: Lys 841 -Phe 856 , B: Arg 858 -Arg 878 , and C: Arg 869 -Lys 885 ), and a model for the complex with cC2 was built for each. The modeling of the complexes was accomplished using the HADDOCK algorithm (35) , which consist of three steps: (i) randomization of orientations and rigid body energy minimization, (ii) semirigid simulated annealing in torsion angle space, and (iii) final refinement in Cartesian space with explicit solvent. The advantage of this docking using HADDOCK consists of the second step where both side chains and backbone at the interface are allowed to move to allow for some conformational rearrangements. All the parameters used in this work were the default parameters supplied in HADDOCK (35) . For cC2, we defined the ambiguous interaction restraints from the residues involved in the binding site. Table 2 . To further investigate which complex of C2-S2⌬ is most favorable and hence most possible, we have estimated the binding free energies of both complexes as follows: ⌬G bind ϭ ⌬G complex Ϫ ⌬G cC2 Ϫ ⌬G S2⌬ , with ⌬G X ϭ ⌬G MM ϩ ⌬G sol ϩ T⌬S. Where ⌬G MM is the molecular mechanics energy in the gas-phase using the sum of energies of the Amber6 force field (33) , ⌬G sol is the solvation free energy, including the electrostatic and the nonpolar contribution using the Divcon program (31, 32) , and T⌬S is the entropy contribution arising from the changes in the degrees of freedom (translational, rotational, and vibrational). Initially, atomic charges, including all atoms, were calculated with Divcon using the PM3 Hamiltonian. For solvation effects the quantum mechanical calculation was coupled to a continuum solvent model using DELPHI to provide all solvation parameters. T⌬S was neglected in our calculations, because it is assumed to be a weak function of size and shape of the interacting proteins (36) . These calculations were intended for qualitative comparison rather than quantitative.
RESULTS
Sequence and Structure of cC2-The structure calculation of cC2 is based on excellent quality three-dimensional 15 N-and 13 C-resolved heteronuclear NOESY spectra of an assumed monomeric protein supported by rotational correlation times of 7.45 Ϯ 0.13 and 7.82 Ϯ 0.29 ns at concentrations of ϳ1.0 mM and 0.4 mM measured by 15 N relaxation. 4 The family of structures shown in Fig. 3A indicates a high definition of the structure of cC2, supported by a root mean square deviation value of 0.68 Å for the backbone atoms of the best 28 structures (see Table 1 for details). The only region of partial disorder is the N terminus where the first five residues of the cC2 construct used in this work are poorly defined. This is consistent with the 15 N relaxation analysis, which indicates this part of the protein to be flexible. 4 The overall topology is depicted in the same orientation in Fig. 3B . The domain has the ␤-sandwich structure expected of a member of the immunoglobulin I-set (37) . One sheet is formed by strands ABED, and the other by strands CЈCFGAЈ. The overall shape of the ␤-sandwich is different from other members of the I-set in that the strands have a strong twist within each sheet in comparison to the relatively straight strands of the other IgI domains. The sheets are less flat but more wrapped around the hydrophobic core than in the related structures giving more an impression of a ␤-barrel like shape than a ␤-sandwich. This leads to one of the most compact structures of an IgI domain with a radius of gyration of only 12. 284 and Asp 280 and the ␤-bulge in the A-strand around residues 215-218 albeit with only one reasonable hydrogen bond from Lys 217 to Glu 236 . Apart from the ␤-bulge itself the A-strand is twisted unusually far away from the G-strand, giving the domain a wedge-like appearance.
Two cysteines (Cys 286 and Cys 293 ) in strands F and G, respectively, are in principle close enough for an interaction of their side chains (see Fig. 3C ). In the majority of structures the thiolgroup of Cys 286 points into the hydrophobic interior of the protein where a potential SH… bond with the benzene ring of Trp 246 may occur with low probability. In contrast, the thiol group of Cys 293 does not have a defined orientation. The distance between the S ␥ atoms in the two cysteines averaged over 28 structures is 4.4 Ϯ 0.4 Å, compared with ϳ2.03 Å for disulfide bridges seen in high resolution crystal structures. As an alternative, a SH…S hydrogen bond is just out of range, because the S-S distance required is ϳ4 Å, as known to exist in crystals of small organic molecules. However, different side-chain rotamers will position the S ␥ atoms sufficiently close to each other. As a result, under reducing conditions an SH…S hydrogen bond could form, whereas under oxidating conditions a disul-fide bridge could form. Because the sample was kept under reducing conditions throughout the NMR experiments, and because no changes in the NMR spectra were noticed over the time of this study it is assumed that the hydrogen bond is the more likely of the two potential interactions.
The alignment of C2 sequences to a selection of IgI domains of known structure is shown in Fig. 2 . The highest sequence similarity to an IgI domain of known structure exists for telokin (sequence identity of cC2 to telokin: 26.7%, to I27: 20.5%, to M5: 18.8%, and to I1: 17.9%). Among all the domains the key residues typical for the IgI fold are extremely well conserved. In contrast to other IgI domains from MyBP-C there are no isoform specific insertions or deletions, so that the overall shape of the C2 domain is expected to be very similar in all isoforms. Both cysteines involved in the potential disulfide bond are conserved in all cardiac and are missing in all other isoforms, with the exception of the chicken isoform.
The usually conserved cis-proline in the BC-loop, part of the definition of the IgI fold, is absent in C2 in all isoforms of MyBP-C. In domains of known structure, e.g. titin M5, I1, and telokin, this cis-proline induces a rather tight bend in the BC-loop, adding to the elongated shapes of these domains. In contrast the same proline is found in titin I27 but in a trans configuration. Structural Relationships of cC2-We compared the structure of cC2 to known IgI structures. Structural alignment with the program CE (38) of cC2 with titin domains I27 and M5, telokin, and titin domain I1 resulted in Z-scores of 5.0, 4.2, 4.7, and 4.7 and root mean square deviation values of 2.7, 3.3, 2.8, and 2.6 Å. Telokin is thus the closest to cC2 by sequence similarity (see above), whereas I27, telokin, and I1 are the closest based on structural similarity. Titin M5 is equally distant based on both criteria. Fig. 4 shows the comparison of these domains with the structure of cC2. The superposition of cC2 with the other domains gave a remarkable result: superposition of cC2 on telokin, gives a low Z-score and a high overall root mean square deviation. Yet there is a remarkably strong structural similarity in the C-terminal half of the structure, in particular with respect to strands C, CЈ, and D, the C-terminal parts of strands F and G, as well as the corresponding loops CCЈD and EF. A similar but slightly less convincing similarity in the C-terminal half of the domain exists with titin domain I1. The similarity of the C-terminal half of cC2 to telokin and titin I1 is in part the result of the presence of the CЈ strand in telokin, I1, and cC2 that is absent in I27 and M5. Also the general orientation of the ␤-strands is highly similar. In contrast, the N-terminal half of cC2 is much shorter, due to its compactness, than that of telokin and I1, and consequently the superposition is rather poor. The superposition with I27 in Fig. 4 provides a marked contrast: the N-terminal half of the proteins, consistent with the high Z-score, is very similar. The main factor in this similarity is the virtually identical length of the N-terminal half of ␤-strands C, F, and G. It was previously noted that I27 is rather short at its N terminus (39), a feature which is prominent in cC2 as well. In contrast to the similarity of the N-terminal half the C-terminal one is highly divergent.
The CЈ strand is originally part of the definition of the IgI fold as seen in telokin (1TLK (40) ) and more recently in the first I-band domain from titin (1G1C (41)). However, in the two other structures determined for immunoglobulin domains from titin, M5 and I27 (1NCT and 1TIT (39, 42) ), this strand is not seen, likewise for domains tw18 and tw26 (1WIT and 1KOA (43)) from twitchin and the first domain from NCAM (2NCM (44)).
Myosin Binding of cC2-Previously it was shown that a shortened fragment of myosin S2 (named S2⌬, see Fig. 1B ) is sufficient for binding to the N-terminal binding site of MyBP-C (13). The latter consists of IgI domains cC1 and cC2 connected by a 100-amino acid long linker containing the mybpc motif also known as cC1C2 (13) . The S2⌬ fragment comprises the first 18 heptads of the S2 coiled coil, from residue 838 to 963 of human cardiac ␤-myosin. The binding of cC2 to S2⌬ was monitored by a NMR titration of 15 Nlabeled cC2 with unlabeled S2⌬ using 1 H-15 N HSQC experiments. The combined 1 H and 15 N chemical shift changes over the range of the titration from 0 to 4 equivalents of S2⌬ are plotted against the sequence of cC2 in Fig. 5A . There are two major groups of substantial chemical shift changes: residues 220 -230 and 280 -300. A few additional residues have small shifts, but these are well below the ͗⌬␦ total ͘ ϩ 1⅐ threshold (in the following we will refer to this threshold as 1⅐). The combined 1 H and 15 N chemical shift changes above the 1⅐ threshold are mapped on a structure cartoon of cC2 in Fig. 5B . The area of the affected amino acids, marked by orange spheres, forms a well defined, compact region on the surface made by ␤-strands G, F, AЈ, and the AЈB loop close to the C terminus of the protein.
To quantify the affinity of cC2 to S2⌬ we have performed isothermal titration calorimetry (ITC) experiments optimized for low affinities (20) . Under the same experimental conditions as the NMR titration the value of k D was determined to be 1.13 Ϯ 0.09 mM (see Fig. 6C ). Fig. 7A shows the electrostatic map of domain cC2 on which the S2⌬ binding site is labeled with a green ellipse. It is interesting to note that despite the otherwise even distribu- tion of charges on the surface of cC2, the S2 binding site is entirely free of positive electrostatic potential with the only exception at His 229 . This arrangement is well conserved in C2 of all isoforms and species: in all available sequences there is no positive charge on the S2 binding site of cC2 (Fig. 2) , and this may indicate the importance of the conserved absence of positive charges in the S2 binding site of cC2.
To further investigate the cC2-S2⌬ interactions by NMR we repeated the binding experiment with S2⌬ containing the point mutation R870H (13) (Fig. 5A ).
Modeling the Complex of cC2
and S2⌬-The protein-protein docking protocol HADDOCK (35) was employed to generate models of the cC2-S2⌬ complex based on the chemical shift data from the wild-type titration for the binding site of cC2 and the charge complementarity between the proteins. The electrostatic potential surface of the proteins is shown in Fig. 7 (A  and B) . The binding site of cC2 has a substantial negative electrostatic potential that could well complement the region of positive electro- static potential between Pro 838 to Asn 885 of S2⌬ (blue box). In contrast all the other regions of S2⌬ present substantial negative electrostatic potentials (red boxes). The surface of S2⌬ suitable for binding to cC2 allows for more than one binding site, so that it was split into three potential binding sites. One complex was created for each of these sites, named complex-A, -B, and -C. Using Haddock interaction energies complex-A and -B are most favorable as judged by the total interaction energy of ϳϪ690 kcal/mol as compared with ϳϪ420 kcal/mol for complex-C (see Table 2 ). This ranking of binding sites is confirmed by the calculation of estimated binding free energies to account for the desolvation penalty for their charged interfaces (see Table 2 ) with almost no difference between complex-A and -B. Although the buried surface area is comparatively similar for all three complexes (ϳ1200 Å 2 ) the difference in binding free energy between complex-C on one hand and complex-A and complex-B on the other hand is substantial as based on both solvation and internal free energy differences. These numbers suggest that there is indeed a specific region in the N terminus of S2⌬ that is well optimized for binding to cC2. At this stage complex-C is energetically unfavorable and thus can be ruled out. In all models of the complex cC2-S2⌬ the N terminus of cC2 points away from S2⌬, so that its C terminus makes the main contact with S2⌬ (see Fig. 7C ). As can be seen in Fig. 7D  complex-B presents a number of close interactions, Among our three models only complex-B has a crucial interaction between cC2 and S2⌬ involving a strong H-bond between Arg 870 (S2⌬) and Glu 296 (cC2), as shown in Fig. 7D (strong H-bond is defined by a short distance between the acceptor and the donor and a higher angle of O…H-N of more than 120°). This interaction does not exist in either complex-A or complex-C. Hence complex-B best represents the experimental data and rules out complex-A and complex-C.
DISCUSSION
Sequence and Structure-The structure of cC2 makes it a typical member of the IgI fold, albeit the most compact one identified to date. The compact shape might be useful in the crowded environment of the relaxed thick filament and was completely unpredictable from an analysis of the sequence alone. Recent high resolution electron microscopy work (45) suggests that there is not much space available around the S1-S2 junction, close to our suggested binding site of cC2. It is also intriguing that this domain is one of the few in addition to telokin and titin I1 that possesses the CЈ ␤-strand. This ␤-strand is part of the original definition of the IgI fold (37) but was not found in a number of members of the IgI family for which structures were determined from titin, twitchin, or neural cell adhesion molecule. Its importance and relevance to the IgI fold was therefore debated in the literature. Opinions range from it being an exception and not relevant to the family as a whole (42, 46) to doubts about the accuracy of the CЈ-less structures, as most of these structures were determined by NMR spectroscopy (41) . Because our structure of cC2 has been determined by NMR, the presence or absence can therefore not be attributed anymore to the choice of method. Instead it is possible that the IgI set could be further divided into two groups depending on the presence or absence of the CЈ strand.
In addition to the general structural similarity to telokin, cC2 contains two cysteines juxtaposed in ␤-strands F and G in a position equivalent to telokin. Strands F and G are of key importance for interaction with myosin for both cC2 and telokin (47) . It is possible to speculate that these cysteines, which are conserved in the cardiac isoform of MyBP-C in most species, should be in their thiol form for most of the time. In this state they could form a hydrogen bond. In the presence of oxidative stress, as in heavily working cardiac muscle, a disulfide bridge might form between them. Disulfide bridges have been shown to increase the thermodynamic as well as mechanical stability of proteins. This extra stability might be necessary to maintain the structure of cC2 and thus the interaction with MyBP-C. Such a stabilization mechanism has been proposed recently for titin domain I1 (48) . MyBP-C-myosin Interaction-The complete binding unit of human cardiac MyBP-C for myosin in vivo is the fragment cC1C2. However, the low affinity and yet the high specificity interaction of the isolated domain cC2 observed in vitro by NMR and ITC provides sufficient detailed data to produce a first structural model for an interaction of these two proteins. The mapping of the binding site on the surface of the cC2 domain results in a well defined group of residues on the F, G, and AЈ strands and the AЈB-loop, all grouped around the C terminus of cC2. The chemical shift changes upon binding are small but significant, typical for an interaction of polar amino acids (49 -51) . There is very little shape complementarity involved in the interaction. Indeed, while strands BED form an inviting concave surface that should be well suited to binding to a round object, like the coiled-coil of S2⌬, the actual binding site is convex. As a result only a relatively small surface area, ϳ1200 Å 2 , is covered as presented in the best model of complex-B. Taken together with the relatively highly charged interface this is consistent with the low binding affinity of 1.1 mM as measured by ITC.
The interactions in the model complex-B are well in agreement with the expectations from the small chemical shift perturbations and the expected charge complementarity. Most amino acids make hydrogen bond and/or salt bridge interactions, e.g. Glu 296 in cC2 with Arg 870 and Arg 869 in S2⌬ or Asp 281 (cC2) with Lys 865 (S2⌬). The only hydrophobic interaction is provided by the contact of Phe 298 (cC2) with Leu 863 (S2⌬). It is important to point out that a number of these interactions involves residues that do not show any chemical shift changes of their backbone amide HN group, albeit close neighbors do. In contrast, some amino acids whose side chains are part of the hydrophobic core of cC2 show considerable chemical shift changes even though they cannot possibly contribute to the binding. The latter is even more important, because the distance between the polypeptide backbones of both proteins is relatively large and most interactions are made by the tips of long amino acids side chains, e.g. Glu, Lys, Leu, and Phe.
The chemical shift changes observed in the titration can thus only be transmitted indirectly through space or bonds from the participating side chains to the backbone. The chemical shift especially of the backbone nitrogen is influenced by a complex mix of parameters ranging from nearby charges to 1 rotations of the own as well as the previous residue in the sequence (52) .
This explains the odd pattern of sequentially alternating residues with and without chemical shift changes in strand G: the side chains of Glu 296 and Phe 298 make contacts at the interface with S2⌬, yet shifts are observed for residues Leu 297 and Val 299 whose side chains point into the hydrophobic core of cC2. Clearly, the origin of the changes in the chemical shifts of the backbone amide group in these two amino acids are side-chain conformational changes in the preceding amino acid.
In the titration with the mutant S2⌬ R870H the chemical shift variations are much weaker, corresponding to an estimated reduction of binding affinity by a factor between 3 and 4, in agreement with the corresponding ITC experiment (13) . To ensure that the observed changes in the titration of S2⌬ and S2⌬ R870H truly correspond to a local change in specific binding, we measured the thermal stability of S2⌬ and S2⌬ R870H and then performed a titration of S2⌬ and S2⌬ R870H with cC1. 4 The thermal stability of both forms of S2⌬ is virtually identical, with a difference in melting temperature of ϳ1°C, well within experimental error. The titration of cC1 with S2⌬ and S2⌬ R870H gave identical results within experimental error (not shown). This indicates that effects of the R870H mutation are indeed local to the binding site of cC2. This result corroborates our NMR observation of the high specificity of cC2-S2⌬ complex formation.
The most striking feature of the mutant titration is not only the loss of binding affinity but the specific response of a small number of residues to the binding of the R870H mutant of S2⌬. The residues on the F-and AЈ-strand and AЈB-loop only show a reduction in chemical shift change; e.g. His 229 shows a significant change in chemical shifts in both titrations. His 229 lies at the edge of the binding site and is able to sample several sidechain conformations that allow interactions with S2⌬ or S2⌬R870H in an almost identical manner.
These experimental observations confirm that the model of complex-B is indeed a reasonable and plausible representation of the real complex, because it predicts an important interaction of Arg 870 with Glu 296 . This interaction is not possible in the S2⌬R870H mutant, because the side chain of a histidine is shorter than that of an arginine. The hydrogen bond and salt bridge interaction between these two amino acids in the model of Complex-B account, however, for only a small part of the total number of interactions between cC2 and S2⌬. As a result overall binding is reduced as the interactions from amino acids along the F-and AЈ-strands and the AЈB-loop are weakened but keep forming the same interface in complex with S2⌬. Around Glu 296 , however, the interactions have to be rearranged. It is expected that Glu 296 could make a new interaction with, e.g. Arg 869 or Arg 871 , which are available nearby. Note that mutations of Arg 869 , in this case to cysteine as well as glycine, have been reported as a cause for FHC (53) . This new arrangement among the neighbors of Glu 296 is assumed to be the origin of the swap in chemical shift responses. The observed hydrogen bonds and/or ionic interactions of Glu 301 on cC2 with Arg 804 on S2⌬ are also important. Glu 301 is the last amino acid in the cC2 construct used in this study. As a result, its side chain is not very well defined in the structure, and the backbone shows increased mobility in the 15 N relaxation experiments. 4 In vivo the following domain cC3 should stabilize Glu 301 . Sequence alignments (not shown) suggest that there is no flexible linker expected between the two domains. Instead we predict that the C-terminal ␤-strand (G) of cC2 continues right into the N-terminal ␤-strand (A) of the following domain cC3 as in the extracellular immunoreceptor CD4 (54) . Consequently, in intact MyBP-C Glu 301 is expected to assume a well defined structure that should improve binding to S2⌬.
The interaction of cC2 with myosin is expected to be similar to that of telokin. The main contribution for myosin light chain kinase binding to myosin comes from the acidic linker 5 between telokin and the kinase domain. However, even the isolated telokin domain binds weakly to myosin, whereas the binding is completely abolished when part of the C terminus of telokin is removed, pointing to a similar binding surface as in cC2 (47) . The similarity in myosin binding sites on cC2 and telokin is further supported by the conservation of key surface residues for the myosin interaction, e.g. 
CONCLUSION
We have used NMR spectroscopy to provide the first structure of domain C2 of human cardiac MyBP-C, the most compact IgI structure determined to date. Combining the structure of cC2 with ITC and NMR interaction data of cC2 with wildtype and mutant myosin S2⌬ and molecular modeling provides us with a realistic structural model of the cC2-S2⌬ complex. This is the first step toward an understanding of the interaction of the MyBP-C N terminus with myosin. This model puts the interaction of an immunoglobulin domain from MyBP-C in the context of other myosin binding IgI domains (telokin/myosin light chain kinase) and for the first time makes suggestions about the importance of individual amino acids at the interface and how they could be correlated to causes of FHC. We expect that these suggestions will stimulate further research on the relationship of the structure and function of MyBP-C and the mutations that have been found to cause FHC.
